Neuronetics Reports Strong Q3 Growth and CEO Transition
I'm PortAI, I can summarize articles.
Neuronetics, Inc. reported strong Q3 growth with a 101% revenue increase to $37.3 million, driven by its Greenbrook clinic acquisition. Key highlights include a 25% growth in U.S. Greenbrook clinic revenue and a strengthened balance sheet with $34.5 million in cash. Despite a decrease in gross margin to 45.9%, the company improved cash management, using only $0.8 million in operations. Neuronetics secured $10 million in funding and expanded Medicaid coverage for its TMS therapy in New York. The company expects total revenue between $147 million and $150 million for 2025 and aims for positive cash flow by year-end.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments